Galapagos NV

GLPG

Equity

ISIN BE0003818359 / Valor 2130343

Euronext - Euronext Amsterdam (2025-04-08)

EUR 22.12+5.23%

Galapagos NV
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Galapagos NV is a company focused on accelerating transformational innovation through groundbreaking science, an entrepreneurial spirit, and a collaborative mindset. In 2022, the company expanded into the field of oncology, CAR-T, and antibody therapy research and development through the acquisitions of CellPoint and AboundBio. These acquisitions have equipped Galapagos NV with end-to-end CAR-T development capabilities, including a decentralized point-of-care manufacturing model and state-of-the-art fully human antibody-based capabilities for the development of next-generation CAR-Ts and biologics.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

Galapagos NV reported total net revenues of €200.1 million for the first nine months of 2024, marking an 11% increase compared to €179.8 million in the same period of 2023. This growth was primarily driven by collaboration revenues, which slightly increased to €181.0 million from €179.8 million in the previous year.

Increased R&D Expenses

The company experienced a significant rise in research and development expenses, which amounted to €238.2 million for the first nine months of 2024, up 42% from €167.2 million in the same period of 2023. This increase was mainly due to higher costs associated with cell therapy and small molecule programs in oncology.

Operating Loss

Galapagos NV reported an operating loss of €125.6 million for the first nine months of 2024, compared to an operating loss of €41.9 million in the same period of 2023. The increased loss was influenced by higher R&D expenses and a decrease in other operating income.

Net Profit from Discontinued Operations

The net profit from discontinued operations for the first nine months of 2024 was €69.2 million, a significant increase from €17.9 million in the same period of 2023. This was largely due to the sale of the Jyseleca® business to Alfasigma, which resulted in a gain recognized in other operating income.

Financial Position

As of September 30, 2024, Galapagos NV held current financial investments, cash, and cash equivalents totaling €3,338.8 million, compared to €3,811.7 million at the end of September 2023. This decrease reflects the company's ongoing investments in its pipeline and strategic initiatives.

Summarized from source with an LLMView Source

Key figures

-24.7%1Y

-66.2%3Y

-88.0%5Y

Performance

29.2%1Y

29.7%3Y

41.0%5Y

Volatility